Description
Overview
This blend pairs hGH Fragment 176-191, CJC-1295 (no DAC) and Ipamorelin for research on the growth hormone axis. It combines a GHRH analog with a ghrelin receptor agonist (GHRP), two compound classes that act through separate pathways and are studied together for their synergistic effect on growth hormone release.
Peptide Sciences Bio supplies hGH Fragment 176-191 + Mod GRF 1-29 + Ipamorelin 12mg Blend as a single lyophilized vial combining hGH Fragment 176-191, CJC-1295 (no DAC) and Ipamorelin for in-vitro and preclinical laboratory investigation. Every batch is supported by independent analytical testing and a published Certificate of Analysis.
Product Specifications
| Product | hGH Fragment 176-191 + Mod GRF 1-29 + Ipamorelin 12mg Blend |
|---|---|
| Format | Pre-mixed lyophilized blend, single vial |
| Contents | 12mg total per vial |
| Component ratio | See batch Certificate of Analysis |
| CJC-1295 (no DAC) CAS | 863288-34-0 |
| Ipamorelin CAS | 170851-70-4 |
| Form | Lyophilized powder |
| Purity | ≥99% per component (HPLC) |
| Documentation | Batch-specific Certificate of Analysis |
Components
- hGH Fragment 176-191: a 16-amino-acid C-terminal fragment of human growth hormone studied in lipid metabolism research.
- CJC-1295 (no DAC): a modified 29-amino-acid GHRH analog that activates the GHRH receptor on pituitary somatotrophs.
- Ipamorelin: a selective synthetic pentapeptide ghrelin receptor agonist with minimal effects on cortisol and prolactin in studies.
GHRH and GHRP Synergy
Growth hormone release is controlled by two main stimulatory signals. GHRH acts on the GHRH receptor and raises cAMP in pituitary somatotrophs. Ghrelin and the synthetic GHRPs act on a separate receptor, GHS-R1a, which works through calcium signaling and also counteracts somatostatin, the hormone that suppresses GH release. Because they use different pathways, research has consistently found that combining a GHRH analog with a GHRP produces a greater GH response than either compound alone, often more than the sum of the two. This synergy is the main reason these compounds are studied together.
Mechanisms Studied
- CJC-1295 (no DAC): binding to the GHRH receptor on pituitary somatotroph cells and cAMP signaling.
- Ipamorelin: selective GH release through GHS-R1a.
- hGH Fragment 176-191: lipolysis and lipid metabolism in adipocyte models, independent of GH receptor activation.
Areas of Study
- Growth hormone secretion and pulsatility research
- GHRH and ghrelin receptor combination pharmacology
- IGF-1 axis research
- Body composition research models
These findings come from laboratory, animal and clinical pharmacology research on the individual components. This research-grade product is not an approved drug product and is not intended for human use.
Related Research Peptides
- hGH Fragment 176-191 6mg
- AOD9604 Peptide 6mg
- CJC-1295 no DAC 2mg (Mod GRF 1-29)
- CJC-1295 no DAC 5mg (Mod GRF 1-29)
- Ipamorelin 2mg
- Ipamorelin Peptide 5mg
Quality & Testing
Every batch of this blend is independently tested for identity and purity before release. Testing includes high-performance liquid chromatography (HPLC) to confirm purity and mass spectrometry (MS) to confirm molecular identity. The batch-specific Certificate of Analysis is available on this page and in our COA library, so researchers can verify the exact material they receive.
Storage & Handling
- Store lyophilized this blend at −20°C, protected from light and moisture.
- Short-term storage at 2–8°C is acceptable for lyophilized material.
- Allow the vial to reach room temperature before opening to limit condensation.
- Handle using standard laboratory practices and appropriate protective equipment.
For laboratory solution preparation, see our Peptide Reconstitution Guide.
Frequently Asked Questions
What is in the hGH Fragment 176-191 + Mod GRF 1-29 + Ipamorelin 12mg Blend?
It contains hGH Fragment 176-191, CJC-1295 (no DAC) and Ipamorelin in a single pre-mixed vial.
Why are these compounds studied together?
GHRH analogs and GHRPs stimulate growth hormone release through different receptors, and research shows that combining them produces a synergistic response.
What is the ratio of each component?
The exact amount of each component in this batch is reported on the Certificate of Analysis available on this page.
Is this product approved for human use?
No. This product is a research-grade material, not an approved drug product, and is not intended for human or veterinary use. Peptide Sciences Bio sells it strictly for laboratory research.
How should it be stored?
Store the lyophilized material at −20°C, away from light and moisture. Short-term storage at 2–8°C is acceptable.
Research Use Only
This product is intended solely for in-vitro research and laboratory experimentation by qualified professionals. It is not a drug, food, supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis, treatment or prevention of any condition. Purchase is restricted to buyers who agree to our Terms of Sale.
Additional information
| Product Form | Lyophilized Powder (Vial) |
|---|
Fragment, Modified GRF, Ipamorelin 12mg (Blend)
$100.00
hGH Fragment 176-191 + Mod GRF 1-29 + Ipamorelin 12mg Blend is a single lyophilized vial combining hGH Fragment 176-191, CJC-1295 (no DAC) and Ipamorelin, designed for preclinical research on the synergy between GHRH and ghrelin receptor signaling in growth hormone release. Each component is ≥99% pure (HPLC), with batch-specific COA available. For laboratory research use only.
Worldwide tracked delivery. Dispatched within 24 hours of order confirmation.
Not satisfied? Return any item within 10 days for a full refund, no questions asked.



